MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.clgc.2018.10.001

Медицинская библиотека · Clinical genitourinary cancer · 2018

Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study.

Masini Cristina, Vitale Maria Giuseppa, Maruzzo Marco, Procopio Giuseppe, de Giorgi Ugo, Buti Sebastiano, Rossetti Sabrina, Iacovelli Roberto, Atzori Francesco, Cosmai Laura, Vignani Francesca, Prati Giuseppe, Scagliarini Sarah, Guida Annalisa, Berselli Annalisa, Pinto Carmine

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Pazopanib has been approved for first-line treatment of patients with metastatic renal-cell carcinoma on the basis of clinical trials that enrolled only patients with adequate renal function. Few data are available on the safety and efficacy of pazopanib in patients with renal insufficiency. This study investigated the effect of kidney function on treatment outcomes in such patients.

PATIENTS AND

METHODS

We retrospectively analyzed data of metastatic renal-cell carcinoma patients treated with pazopanib from January 2010 to June 2016 with respect to renal function. Patients with Modification of Diet in Renal Disease ≤ 60 mL/min/1.73 m2 (group A) were compared to patients with Modification of Diet in Renal Disease > 60 mL/min/1.73 m2 (group B) in terms of progression-free survival, toxicities, response rates, and overall survival.

RESULTS

A total of 229 patients were included: 128 in group A and 101 in group B. Median progression-free survival was 14 months (95% confidence interval [CI], 9.4-18.5) and 17 months (95% CI, 11.4-22.8), and overall survival was 30.5 months (95% CI, 8-53) and 41.4 months (95% CI, 21-62) for group A and group B, respectively, with no significant difference (P = .6). No significant difference between the 2 groups was reported in the incidence of adverse events. Dose reductions were more frequent in group A patients (66% vs. 36%; P = .04).

CONCLUSION

Although the dose of pazopanib was reduced more frequently in patients with renal impairment, kidney function at therapy initiation does not adversely affect the safety and efficacy of pazopanib.

Для цитирования: Masini Cristina, Vitale Maria Giuseppa, Maruzzo Marco, Procopio Giuseppe, de Giorgi Ugo, Buti Sebastiano, Rossetti Sabrina, Iacovelli Roberto, Atzori Francesco, Cosmai Laura, Vignani Francesca, Prati Giuseppe, Scagliarini Sarah, Guida Annalisa, Berselli Annalisa, Pinto Carmine. Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study.. Clinical genitourinary cancer. 2018. DOI: 10.1016/j.clgc.2018.10.001.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.